Israeli Biomed Stocks: Not What the Broker Ordered

While U.S. shares just finished a nice five-year run, their Israeli counterparts lost 60%. The reason: No profits.

Uri Tomer
Uri Tomer
Send in e-mailSend in e-mail
A biomed business model requires big investments over many years in research and development.Credit: Bloomberg

Comments